ReviewNature reviews. Urology2014
The genetic epidemiology of prostate cancer and its clinical implications.
Review in Nature reviews. Urology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Association between periodontal disease and prostate cancer: a systematic review and meta-analysis.Medicina oral, patologia oral y cirugia bucal · 2021Pooled it
- Modeling human prostate cancer progression in vitro.Carcinogenesis · 2019Pooled it
- Pooled it
- Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study.International journal of cancer · 2017Pooled it
- Association between germline homeobox B13 (HOXB13) G84E allele and prostate cancer susceptibility: a meta-analysis and trial sequential analysis.Oncotarget · 2016Pooled it
- Large-scale association analysis in Asians identifies new susceptibility loci for prostate cancer.Nature communications · 2015Pooled it
- A genome-wide pleiotropy scan for prostate cancer risk.European urology · 2015Pooled it
- A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.Nature genetics · 2014Pooled it
- Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT.Prostate cancer and prostatic diseases · 2020Trial
- Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance.Carcinogenesis · 2016Trial
- An Integrative Methylation-Metabolism Gene Signature Defines Prognosis and Immunosuppressive Microenvironment in Prostate Cancer.Chemical biology & drug design · 2026Article
- Cancer disparities: an extensive review.Ecancermedicalscience · 2026Review
- A four-miRNA serum panel as a diagnostic biomarker for prostate cancer: an exploratory and validation study.Frontiers in oncology · 2026Article
- Reprogrammed Lipid Metabolism-Associated Therapeutic Vulnerabilities in Prostate Cancer.International journal of molecular sciences · 2025Review
- Integrative genomic and bioinformatic prioritization of drug repurposing candidates for prostate cancer.BMC pharmacology & toxicology · 2025Article
- Prostate cancer risk reduction: promising prevention practices and insights.Annals of medicine and surgery (2012) · 2025Review
- From conventional therapy to novel nano-based approaches. A focus on prostate cancer.Nanomedicine (London, England) · 2025Review
- VADEr: Vision Transformer-Inspired Framework for Polygenic Risk Reveals Underlying Genetic Heterogeneity in Prostate Cancer.medRxiv : the preprint server for health sciences · 2025Article
- Prostate cancer diagnosis and management: current practices in Africa a consultant-based survey.Frontiers in urology · 2025Article
- Association of composite dietary antioxidant index with high risk of prostate cancer in middle-aged and elderly men: insights from NHANES.Frontiers in immunology · 2025Article
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Worldwide, familial and epidemiological studies have generated considerable evidence of an inherited component to prostate cancer. Indeed, rare highly penetrant genetic mutations have been implicated. Genome-wide association studies (GWAS) have also identified 76 susceptibility loci associated with prostate cancer risk, which occur commonly but are of low penetrance. However, these mutations interact multiplicatively, which can result in substantially increased risk. Currently, approximately 30% of the familial risk is due to such variants. Evaluating the functional aspects of these variants would contribute to our understanding of prostate cancer aetiology and would enable population risk stratification for screening. Furthermore, understanding the genetic risks of prostate cancer might inform predictions of treatment responses and toxicities, with the goal of personalized therapy. However, risk modelling and clinical translational research are needed before we can translate risk profiles generated from these variants into use in the clinical setting for targeted screening and treatment.
Indexed as
Identifiers
24296704What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.